Methylation profiling of human germ cell cancers of testicular and ovarian origin
Ontology highlight
ABSTRACT:
INSTRUMENT(S): Illumina iScan
ORGANISM(S): Homo sapiens
SUBMITTER: Lambert Dorssers C J
PROVIDER: E-MTAB-5842 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
Similar Datasets
Project description:RNA-seq analysis of two Testicular Germ Cell Cancers (TGCC) of patients with chemotherapy-resistant disease. Purpose of the study was to resolve the early development and progression of the disease by whole genome sequencing, RNA-seq and methylation profiling of the primary tumor, and the targeted sequencing of purified tumor components (embryonal carcinoma (EC), teratoma (TE), and yolk sac tumor (YST), precursor lesion (Germ Cell Neoplasia In Situ (GCNIS)), and metastases. Whole genome sequencing for the two patients, T6107 and T3209, have been deposited with the European Nucleotide Archive under project accession number PRJEB20644 / study accession ERP022815 ( http://www.ebi.ac.uk/ena/data/search?query=ERP022815 ).
2019-02-11 | E-MTAB-5746 | biostudies-arrayexpress
Project description:Gene expression profiling of human type II testicular germ cell cancers and cell lines.
2018-10-31 | E-MTAB-6312 | biostudies-arrayexpress
Project description:Germ cell tumors (GCT) originate from germ cells at different developmental stages (GCT type I – V) They are thought to inherit their methylation profile from (early embryonic) germ cells which undergo a characteristic epigenetic “reset” during maturation. This study aims to provide insight into the developmental timing and underlying biology of the various subtypes of GCTs and their (embryonic) cells of origin by identifying specific and global methylation differences between GCT subtypes. In total, 91 type I-IV GCTs and four cell lines were profiled using the Illumina HumanMethylation450 BeadChip (450K) platform. The data were pre-processed using a validated pipeline and analyzed using an in-house generated extension of the annotation manifest. Marked methylation differences were identified between GCT subtypes both on the global and local level (i.e. differentially methylated regions, imprinting control regions, promoters, etc). GCT subtypes indeed show major similarities to specific stages of (early) developing embryonic germ cells with regard to their methylation profile. The extended annotation manifest for the Illumina 450K platform and methylation datasets are readily available on GEO (GEO accession: GSE58538, GPL18809), providing an integrated hypothesis generating data source for future research. 91 germ cell tumors of various histologies were investigated for their methylation profile. Methylation detection was performed using Illumina’s HumanMethylation450 BeadChip. 14 type I teratomas (TE) were included of which 6 were located sacral (3 male: I.TE.s.m; 3 female: I.TE.s.f), 4 were located in the testis (I.TE.t) and 3 were located in the ovary (I.TE.o). 30 pure embryonal carcinomas (EC) were included as well as 21 mixed non seminomas (mNS). 12 seminomas of the testis (SE) were included as well as 4 dysgerminomas (their couterpart in the ovary). Finally, 4 spermatocytic seminomas (SS) and three dermoid cysts were analyzed. For a detailed overview the histological classification of germ cell tumors please see the publication linked to this data or associated literature [1-3]. Four cell lines were included, al modelling type II GCTs. Cell lines derived from EC include NT2[4-8], NCCIT [5, 9] and 2102EP[4-8]. TCam-2 closely resembles SE [10-12]. 1. Oosterhuis, J.W. and L.H. Looijenga, Testicular germ-cell tumours in a broader perspective. Nat Rev Cancer, 2005. 5(3): p. 210-22. 2. Looijenga, L.H., Human testicular (non)seminomatous germ cell tumours: the clinical implications of recent pathobiological insights. J Pathol, 2009. 218(2): p. 146-62. 3. Woodward, P.J., et al., Testicular germ cell tumors, in World Health Organization Classification of Tumours Pathology and Genetics of the Urinary System and Male Genital Organs., J.N. Eble, et al., Editors. 2004, IARC Press: Lyon. p. 17-278. 4. Andrews, P.W., et al., A comparative study of eight cell lines derived from human testicular teratocarcinoma. Int J Cancer, 1980. 26(3): p. 269-80. 5. Andrews, P.W., et al., Comparative analysis of cell surface antigens expressed by cell lines derived from human germ cell tumours. Int J Cancer, 1996. 66(6): p. 806-16. 6. Wang, N., et al., Nonrandom abnormalities in chromosome 1 in human testicular cancers. Cancer Res, 1980. 40(3): p. 796-802. 7. Fogh, J. and G. Trempe, New Human Tumor Cell Lines, in Human Tumor Cells in Vitro, J. Fogh, Editor. 1975, Springer US. p. 115-159. 8. Fogh, J., Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors. Natl Cancer Inst Monogr, 1978(49): p. 5-9. 9. Teshima, S., et al., Four new human germ cell tumor cell lines. Lab Invest, 1988. 59(3): p. 328-36. 10. Eckert, D., et al., TCam-2 but not JKT-1 cells resemble seminoma in cell culture. Cell Tissue Res, 2008. 331(2): p. 529-38. 11. de Jong, J., et al., Further characterization of the first seminoma cell line TCam-2. Genes Chromosomes Cancer, 2008. 47(3): p. 185-96. 12. Mizuno, Y., et al., [Establishment and characterization of a new human testicular germ cell tumor cell line (TCam-2)]. Nihon Hinyokika Gakkai Zasshi, 1993. 84(7): p. 1211-8.
2015-02-26 | E-GEOD-58538 | biostudies-arrayexpress
Project description:Identification of copy number alterations of HPV-positive and HPV-negative vulvar squamous cell carcinomas (VSCC) and vulvar intraepithelial neoplasias (VIN), with special focus on VIN with and without VSCC, the latter group being defined as VIN with no VSCC development during >10 year follow-up.
2018-07-01 | E-MTAB-6113 | biostudies-arrayexpress
Project description:T-cell/histiocyte rich B cell lymphoma (THRBL) and nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) share some morphological characteristics, including a prominent stromal reaction, but display a markedly different prognosis. To investigate the difference between the stromal reactions of these lymphomas at the molecular level, we performed microarray expression profiling on a series of THRBL and NLPHL cases. Experiment Overall Design: Microarray expression profiling was performed for 10 NLPHL and 10 THRBL cases. A pool of 5 reactive lymph nodes was included as a reference sample.
2009-12-18 | E-GEOD-7788 | biostudies-arrayexpress
Project description:Comparison of t(11;18)-positive MALT lymphoma to t(11;18)-negative MALT lymphoma, with a special focus on the NF-KB pathway and it's targets 8 t(11;18)-negative and 6 t(11;18)-positive cases of MALT lymphoma, as well as six spleen control samples (1 mix of spleens and 5 singular spleen samples)
2010-11-25 | E-GEOD-25550 | biostudies-arrayexpress
Project description:Germ cancer cell lines were genotyped using the Infinium global screening array.
2022-06-01 | E-MTAB-9266 | biostudies-arrayexpress
Project description:GSA from 562 out of 1841 patients with severe decompensated cirrhosis from the DECISION project. The DECISION project aims to discover more personalized combinatorial therapies for patients with decompensation of cirrhosis. This will be achieved by using readily available clinical data, prospectively collected in a homogenous manner from large clinical studies, with the corresponding standardized biobank samples that will produce omics data once they are fully analyzed. The data generated and analyzed in DECISION will directly serve as a basis for accomplishing the objectives of the project, i.e.: 1. Improving our knowledge of the pathophysiology of decompensation of cirrhosis by integrating results of high-throughput multi-omic profiling with comprehensive clinical data from fully characterized patients with available biological samples. 2. Identifying novel combinatorial therapies for patients with decompensation of cirrhosis to prevent death. 3. Developing 2 tests: One predicting the outcome of patients with decompensation of cirrhosis when treated with standard treatment (prognostic test), and the other identifying patients who will respond to the novel combinatorial therapy (test for response).
2024-12-18 | E-MTAB-12555 | biostudies-arrayexpress
Project description:GSA from 278 out of 1841 patients with severe decompensated cirrhosis from the DECISION project. The DECISION project aims to discover more personalized combinatorial therapies for patients with decompensation of cirrhosis. This will be achieved by using readily available clinical data, prospectively collected in a homogenous manner from large clinical studies, with the corresponding standardized biobank samples that will produce omics data once they are fully analyzed. The data generated and analyzed in DECISION will directly serve as a basis for accomplishing the objectives of the project, i.e.: 1. Improving our knowledge of the pathophysiology of decompensation of cirrhosis by integrating results of high-throughput multi-omic profiling with comprehensive clinical data from fully characterized patients with available biological samples. 2. Identifying novel combinatorial therapies for patients with decompensation of cirrhosis to prevent death. 3. Developing 2 tests: One predicting the outcome of patients with decompensation of cirrhosis when treated with standard treatment (prognostic test), and the other identifying patients who will respond to the novel combinatorial therapy (test for response).
2024-12-18 | E-MTAB-12554 | biostudies-arrayexpress
Project description:GSA from 387 out of 1841 patients with severe decompensated cirrhosis from the DECISION project. The DECISION project aims to discover more personalized combinatorial therapies for patients with decompensation of cirrhosis. This will be achieved by using readily available clinical data, prospectively collected in a homogenous manner from large clinical studies, with the corresponding standardized biobank samples that will produce omics data once they are fully analyzed. The data generated and analyzed in DECISION will directly serve as a basis for accomplishing the objectives of the project, i.e.: 1. Improving our knowledge of the pathophysiology of decompensation of cirrhosis by integrating results of high-throughput multi-omic profiling with comprehensive clinical data from fully characterized patients with available biological samples. 2. Identifying novel combinatorial therapies for patients with decompensation of cirrhosis to prevent death. 3. Developing 2 tests: One predicting the outcome of patients with decompensation of cirrhosis when treated with standard treatment (prognostic test), and the other identifying patients who will respond to the novel combinatorial therapy (test for response).
2024-12-18 | E-MTAB-12553 | biostudies-arrayexpress